This Week in General Medicine — May 28, 2026

Welcome to This Week in General Medicine. This week we're covering 8 notable papers spanning major therapeutic updates in oncology, endocrinology, and pulmonology; new strategies in diagnostics and screening; and a look at the future of health systems and the global burden of disease. Let's dive in.

We'll begin with three major clinical trials published this week, each evaluating novel treatments for common and serious conditions.

First, in The Lancet, the ATTAIN-2 trial reports on orforglipron, a once-daily, oral, non-peptide GLP-1 receptor agonist for adults with obesity and type 2 diabetes [8]. This is important as it offers a potential alternative to the injectable GLP-1 agonists that dominate the market. In this phase 3 trial, over 1600 participants were randomized to one of three doses of orforglipron or placebo for 72 weeks. The results were dose-dependent and statistically significant. Using the treatment regimen estimand, the highest dose of orforglipron, 36 milligrams, led to a mean bodyweight reduction of 9.6 percent from baseline, compared to just 2.5 percent with placebo. The lower doses of 6 and 12 milligrams also resulted in significant weight loss of 5.1 and 7.0 percent, respectively. Beyond weight, all prespecified cardiometabolic measures, including HbA1c, also showed statistically significant improvements with orforglipron. As expected with this class of medication, the most common adverse events were mild-to-moderate gastrointestinal issues, like nausea and vomiting, which were most prominent during the dose-escalation phase. Treatment discontinuations due to adverse events were higher in the orforglipron groups, ranging from 6 to 10 percent, compared to 4 percent in the placebo group. These findings position orforglipron as a promising oral option for managing both obesity and type 2 diabetes.

Staying in The Lancet, we turn to oncology with the PACT-21 CASSANDRA trial [7]. This study addressed a critical question in the management of resectable or borderline resectable pancreatic ductal adenocarcinoma: which preoperative chemotherapy regimen is superior? The trial randomized 260 patients in Italy to either a four-month course of PAXG—a combination of cisplatin, nab-paclitaxel, capecitabine, and gemcitabine—or the standard regimen, mFOLFIRINOX. The primary endpoint was event-free survival. The results were definitive. The PAXG regimen significantly prolonged median event-free survival to 16.0 months, compared with 10.2 months for mFOLFIRINOX. This corresponds to a hazard ratio of 0.63, a clinically meaningful improvement. Grade 3 or worse adverse events were common in both groups, occurring in 66 percent of patients receiving PAXG and 61 percent receiving mFOLFIRINOX. The authors conclude that preoperative PAXG could be considered a new standard option for this patient population and should serve as the comparator for future clinical trials.

Rounding out our therapeutics section, we have a more complex story from two large trials also published in The Lancet [5]. The ALIENTO and ARNASA trials evaluated astegolimab, an antibody targeting the ST2 receptor, for preventing exacerbations in patients with COPD. This pathway is implicated in both neutrophilic and eosinophilic inflammation, suggesting a potential benefit regardless of baseline eosinophil counts. Both were randomized, placebo-controlled trials testing astegolimab given every 2 weeks or every 4 weeks. The results, however, were inconsistent. In the ALIENTO trial, the every-2-week dose was associated with a modest but statistically significant 15 percent reduction in the rate of moderate or severe exacerbations compared to placebo. The every-4-week dose showed no significant benefit. But in the ARNASA trial, these findings were not replicated. The every-2-week dose did not meet statistical significance, with a p-value of 0.068. In an unexpected twist, the every-4-week dose in ARNASA did show a statistically significant 18 percent reduction in exacerbations. The safety profile was generally similar across all groups. This mixed picture from two pivotal trials creates uncertainty. While the findings suggest a potential role for targeting the ST2/IL-33 pathway, the inconsistent dose-response and differing trial outcomes make it difficult to draw firm conclusions about the clinical utility of astegolimab at this time.

Next, we turn to two studies from JAMA that explore new ways to identify and manage disease earlier, focusing on screening and diagnostics.

The first study looks at population-based screening for early-stage type 1 diabetes in children [3]. Detecting the disease in its presymptomatic stages—stage 1 with autoantibodies and normoglycemia, or stage 2 with autoantibodies and dysglycemia—is key for implementing therapies that can delay clinical onset. This large study from Bavaria, Germany, screened over 220,000 children aged roughly 2 to 11 years for islet autoantibodies. They found an adjusted population frequency of early-stage type 1 diabetes of 0.3 percent. During a median follow-up of nearly 6 years, the 5-year progression rate from an early-stage diagnosis to clinical, or stage 3, diabetes was about 36 percent. Critically, this progression rate was not significantly different between children with a first-degree family history of type 1 diabetes and those without. This finding is significant because it suggests that screening can be valuable for the general pediatric population, not just for those with known genetic risk. These results provide crucial data to inform discussions around broader, population-level screening programs and the implementation of disease-modifying therapies.

Our second paper in this section is the FAST randomized clinical trial, which evaluated the impact of a rapid antimicrobial susceptibility testing, or AST, method for gram-negative bacteremia [6]. In an era of rising antimicrobial resistance, getting the right antibiotic on board quickly is paramount. This trial, conducted in several countries with high resistance rates, randomized 850 patients to either receive results from a rapid AST method performed directly on positive blood cultures, or to undergo standard testing alone. The primary outcome was a composite measure called the desirability of outcome ranking, or DOOR, at day 30, which combines survival with the absence of deleterious events. The results were clear: the rapid AST method was not superior to standard testing. The probability that outcomes were more favorable in the rapid testing group was 48.8 percent, with a 95 percent confidence interval that crossed the 50 percent threshold for superiority. While the rapid test did lead to faster antibiotic changes by a median of 14 hours, it did not translate into better overall clinical outcomes, including 30-day mortality or length of stay. An interesting prespecified subgroup analysis found that among patients with carbapenem-resistant infections, the time to effective therapy was substantially shorter in the rapid testing group—by a median of 18 hours. This suggests that while rapid AST may not be a game-changer for all gram-negative bloodstream infections, it might hold value in specific high-risk populations or settings where multidrug resistance is a major concern.

Finally, we zoom out to look at the bigger picture, with three papers on public health, health policy, and the large-scale challenges facing medicine.

First, from The Lancet, we have the sobering results of the 2023 Global Burden of Disease study on mental disorders [2]. This comprehensive analysis provides a global snapshot of the prevalence and impact of 12 major mental disorders from 1990 to 2023. The numbers are staggering. In 2023, there were an estimated 1.17 billion prevalent cases of mental disorders worldwide. The age-standardized prevalence rate has increased by 24 percent since 1990. The burden, measured in disability-adjusted life-years or DALYs, is immense. Mental disorders are now the fifth leading cause of global DALYs, climbing from 12th place in 1990. Perhaps most strikingly, they are now the single leading cause of years lived with disability, or YLDs, globally, accounting for over 17 percent of all YLDs. The main drivers of this burden are anxiety disorders and major depressive disorder. These data paint a stark picture of a growing global mental health crisis and underscore the urgent need for scalable, effective interventions and improved access to care worldwide.

Connecting this large-scale problem to a potential solution, a Viewpoint in JAMA proposes a radical rethinking of primary care in the United States [4]. The authors note that over a third of adults in the United States lack access to primary care, which is increasingly treated as a commodity rather than a common good. They argue that state-level efforts to bolster primary care are often fragmented and undermined by the complex, multi-payer insurance system. Their proposed solution is to establish a 'primary care common fund'. Under this model, states would pool primary care spending from all payers—including Medicare, Medicaid, and private insurers—into a single fund. This fund would then pay primary care practices directly, potentially using alternative payment models that move away from fee-for-service. The authors argue this would create stable and equitable funding, reduce administrative burdens, and strengthen primary care as a public utility, all without disrupting the delivery of specialty care or other parts of the health system. It's a bold proposal aimed at tackling the foundational crisis in primary care access and financing.

Finally, a new Lancet Commission report provides a forward-looking vision for 'precision health' [1]. The commission argues for an expanded definition of precision health that goes far beyond genomics and molecular biomarkers. They advocate for a model that integrates diverse data streams—from clinical and environmental data to social determinants of health—to deliver more effective and, crucially, more equitable health outcomes for all populations. The report emphasizes that the goal of data-driven healthcare should not be just to tailor treatments for a select few, but to use data to understand and close health disparity gaps. It serves as a powerful call to action to ensure that as medicine becomes more technologically advanced and personalized, it does so in a way that promotes equity rather than exacerbating existing inequalities.

If you only have time for one paper this week, make it the PACT-21 CASSANDRA trial in The Lancet [7]. It found that the preoperative PAXG chemotherapy regimen significantly improved event-free survival over mFOLFIRINOX for patients with resectable pancreatic cancer, and it should be considered a new standard option and the comparator for future trials in this setting.

Here are the key takeaways from this week in General Medicine.

First, in resectable or borderline resectable pancreatic cancer, consider preoperative PAXG chemotherapy, which demonstrated superior event-free survival compared to mFOLFIRINOX in a head-to-head trial [7].

Second, orforglipron, a new once-daily oral GLP-1 agonist, shows significant weight loss and glycemic control in patients with obesity and type 2 diabetes, offering a non-injectable, non-peptide option in this class [8].

Third, general population screening for early-stage type 1 diabetes in children is feasible and identifies cases that progress to clinical disease at similar rates regardless of family history, supporting broader screening initiatives [3].

Fourth, for most patients with gram-negative bacteremia, a rapid antimicrobial susceptibility test did not improve overall clinical outcomes at 30 days compared to standard methods, though it did speed up antibiotic modifications and may have a role in high-resistance settings [6].

Finally, the global burden of mental illness continues to grow, with mental disorders now representing the single leading cause of years lived with disability worldwide, underscoring the urgent need for better access to mental healthcare [2].

That's your roundup for This Week in General Medicine. The full transcript and references are available on the episode page in your AudioScholar library. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week.